

Edited by

A VICTOR HOFFBRAND

DOUGLAS R HIGGS

DAVID M KEELING

ATUL B MEHTA

Seventh Edition

Postgraduate Haematology



WILEY Blackwell

Companion website

This book has a companion website:

www.wiley.com/go/hoffbrand/ph7

with:

- Figures and tables from the book for downloading

Postgraduate Haematology

EDITED BY

A Victor Hoffbrand MA, DM, FRCP, FRCPath, FRCP (Edin),
DSc, FMedSci

Emeritus Professor of Haematology, University College London,
London, UK

Douglas R Higgs MD, FRCP, FRS

Professor of Molecular Haematology & Director, Weatherall
Institute of Molecular Medicine, John Radcliffe Hospital,
Oxford, UK

David M Keeling BSc, MD, FRCP, FRCPath

Consultant Haematologist, Oxford Haemophilia and Thrombosis
Centre, Oxford University Hospitals, Oxford, UK

Atul B Mehta MA, MD, FRCP, FRCPath

Consultant Haematologist, Lysosomal Storage Disorders Unit,
Department of Haematology, Royal Free Hospital, London, UK

Seventh Edition

WILEY Blackwell

This edition first published 2016 © 2016, 2011, 2005 by John Wiley & Sons Ltd

First published as *Tutorials in Postgraduate Haematology* © William Heinemann Ltd 1972

Second edition 1981 published © Butterworth Ltd

Third edition 1989 published © Butterworth Ltd

Fourth edition 1999 published © Butterworth-Heinmann Ltd

Registered office: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work

as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Postgraduate haematology / edited by A. Victor Hoffbrand, Douglas R. Higgs, David M. Keeling, Atul B. Mehta. – Seventh edition.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-118-85432-7 (cloth)

I. Hoffbrand, A. V., editor. II. Higgs, Douglas R., editor. III. Keeling, David (David Michael), editor. IV. Mehta, Atul B., editor.

[DNLM: 1. Blood Physiological Phenomena. 2. Hematologic Diseases. 3. Leukemia-blood. 4. Thrombosis-blood. WH 100]

RC633

616.1'5-dc23

2015019099

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image: GettyImages-464401418 by Frentusha

Contents

[Contributor list](#)

[Preface to the seventh edition](#)

[Preface to the first edition](#)

[Chapter 1 Stem cells and haemopoiesis](#)

[Introduction](#)

[Hierarchical organization and lineage relationships in the adult haemopoietic system](#)

[Sites of adult haemopoiesis](#)

[Development of HSCs](#)

[Haemopoietic-supportive microenvironments](#)

[Haemopoietic regenerative and replacement therapies](#)

[Selected bibliography](#)

[Chapter 2 Erythropoiesis](#)

[Introduction](#)

[The origins of erythroid cells during development](#)

[Specifying the erythroid lineage](#)

[Expression of critical transcription factors specifies the erythroid lineage](#)

[Terminal maturation of committed erythroid cells](#)

[Changes in the expression of transcription factors during terminal maturation](#)

[Changes in the expression of erythroid proteins during terminal maturation](#)

[Control of erythropoiesis via cell signalling](#)

[The erythroid niche](#)

[Red cell senescence and clearance](#)

[Assessing erythropoiesis](#)

[Conclusions](#)

[Selected bibliography](#)

[Chapter 3 Iron metabolism, iron deficiency and disorders of haem synthesis](#)

[Introduction](#)

[Distribution of body iron](#)

[Proteins important in iron metabolism](#)

[Intracellular iron homeostasis](#)

[Normal iron balance](#)

[Iron absorption](#)

[Iron uptake by erythroid cells](#)

[Haem synthesis and mitochondrial iron metabolism](#)

[Intracellular transit iron and plasma non-transferrin-bound iron](#)

[Breakdown of haemoglobin](#)

[Diagnostic methods for investigating iron metabolism](#)

[Iron deficiency anaemia](#)

[Pathological alterations in haem synthesis](#)

[Selected bibliography](#)

[Chapter 4 Iron overload](#)

[Introduction](#)

[Hereditary haemochromatosis](#)

[Iron-loading anaemias](#)

[Selected bibliography](#)

[Chapter 5 Megaloblastic anaemia](#)

[Introduction](#)

[Underlying basic science](#)

[Clinical features](#)

[Haematological findings](#)

[Cobalamin](#)

[Folate](#)

[General management of megaloblastic anaemia](#)

[Prophylactic folic acid](#)

[Megaloblastic anaemia not due to cobalamin or folate deficiency or altered metabolism](#)

[Other nutritional anaemias](#)

[Selected bibliography](#)

[Chapter 6 Haemoglobin and the inherited disorders of globin synthesis](#)

[Introduction](#)

[The structure, genetic control and synthesis of haemoglobin](#)

[Classification of the disorders of haemoglobin](#)

[The thalassaemias and related disorders](#)

[Structural haemoglobin variants related to thalassaemia \(Table 6.3\)](#)

[Acknowledgement](#)

[Selected bibliography](#)

[Chapter 7 Sickle cell disease](#)

[Introduction](#)

[Geographic distribution of sickle mutation](#)

[Pathophysiology](#)

[Clinical manifestations](#)

[Variant sickle cell syndromes](#)

[Diagnosis](#)

[Therapy](#)

[Selected bibliography](#)

[Chapter 8 Hereditary disorders of the red cell membrane and disorders of red cell metabolism](#)

[Haemolysis](#)

[Red cell membrane disorders](#)

[The clinical phenotypes of hereditary membrane disorders](#)

[Defects of red cell metabolism](#)

[The glycolytic pathway \(Embden-Meyerhof pathway\).](#)

[Defence against oxidative stress: the production of reducing power](#)

[Pentose phosphate pathway \(hexose monophosphate shunt\)](#)

[Glutathione](#)

[Nucleotide metabolism](#)

[Selected bibliography](#)

[Chapter 9 Acquired haemolytic anaemias](#)

[Introduction](#)

[Immune haemolytic anaemias](#)

[Non-immune acquired haemolytic anaemias](#)

[Selected bibliography](#)

[Chapter 10 Inherited aplastic anaemia/bone marrow failure syndromes](#)

[Introduction](#)

[Fanconi anaemia](#)

[Dyskeratosis congenita](#)

[Shwachman-Diamond syndrome \(SDS\)](#)

[Diamond-Blackfan anaemia \(DBA\)](#)

[Congenital dyserythropoietic anaemia \(CDA\)](#)

[Congenital and cyclical neutropenias](#)

[Thrombocytopenia with absent radii \(TAR\)](#)

[Congenital amegakaryocytic thrombocytopenia \(CAMT\)](#)

[Conclusion](#)

[Acknowledgements](#)

[Selected bibliography](#)

[Chapter 11 Acquired aplastic anaemia and paroxysmal nocturnal haemoglobinuria](#)

[Acquired aplastic anaemia](#)

[Paroxysmal nocturnal haemoglobinuria](#)

[Suggested further reading](#)

[Selected bibliography](#)

[Chapter 12 Red cell immunohaematology](#)

[Introduction](#)

[Blood group systems](#)

[The red cell membrane and chemistry of blood group antigens](#)

[Blood group antibodies](#)

[Clinical significance of red cell antibodies](#)

[Detection of red cell antigen-antibody reactions](#)

[Molecular techniques for blood grouping](#)

[The ABO system](#)

[The Lewis system](#)

[P blood groups](#)

[I and i antigens and antibodies](#)

[The Rh system](#)

[The MNS system](#)

[The Kell blood group system](#)

[Some other blood group systems](#)

[Polyagglutinable red cells](#)

[The biological significance of blood group antigens](#)

[Selected bibliography](#)

[Chapter 13 Clinical blood transfusion](#)

[Introduction](#)

[Blood transfusion and regulatory aspects](#)

[The blood donor \(Tables 13.1 and 13.2\)](#)

[Transfusion-transmitted infection \(TTI\)](#)

[Laboratory tests on blood donations](#)

[Clinical and laboratory transfusion practice](#)

[Laboratory tests in patients](#)

[Special requirements for the selection of blood](#)

[Safe administration of blood](#)

[Complications of blood transfusion](#)

[Haemovigilance](#)

[Appropriate use of blood and alternatives to allogeneic blood transfusion](#)

[Selected bibliography](#)

[Chapter 14 Phagocytes](#)

[Introduction](#)

[Mechanisms of phagocyte function](#)

[Production, structure and dysfunction of phagocytes](#)

[Selected bibliography](#)

[Chapter 15 Lysosomal storage disorders](#)

[Lysosomes](#)

[Pathophysiology of lysosomal storage disorders](#)

[Prevalence](#)

[Diagnosis](#)

[General aspects of therapy](#)

[Prognosis](#)

[Clinical manifestations](#)

[Selected bibliography](#)

[Chapter 16 Normal lymphocytes and non-neoplastic lymphocyte disorders](#)

[Introduction](#)

[The anatomy of the immune system](#)

[Nature of the antigen-specific receptors on T and B cells](#)

[Generation of antigen-specific receptors on T and B lymphocytes](#)

[B lymphopoiesis](#)

[T-cell production and selection in the thymus](#)

[The B-cell repertoire](#)

[The T-cell repertoire](#)

[Natural killer cells](#)

[The immune response](#)

[Cytokines and their classification](#)

[Chemokines and their classification](#)

[Interpretation of blood lymphocyte counts](#)

[Infectious mononucleosis](#)

[Selected bibliography](#)

[Chapter 17 The spleen](#)

[Evolution of the spleen](#)

[Structure and function](#)

[Splenomegaly and hypersplenism](#)

[Splenectomy](#)

[Hyposplenism](#)

[Selected bibliography](#)

[Chapter 18 The molecular basis of haematological malignancies](#)

[Introduction](#)

[The cancer genome](#)

[Classes of DNA mutations](#)

[Inherited predisposition to haematological cancers](#)

[From genotype to phenotype](#)

[Clonal evolution and subclonal architecture of haematological cancers](#)

[Selected bibliography](#)

[Chapter 19 Laboratory diagnosis of haematological neoplasms](#)

[Introduction](#)

[Blood count and blood film](#)

[Bone marrow aspirate](#)

[Bone marrow trephine biopsy](#)

[Cytochemistry](#)

[Histology](#)

[Flow cytometric immunophenotyping](#)

[Immunohistochemistry](#)

[Cytogenetic analysis](#)

[Fluorescence *in situ* hybridization](#)

[Molecular genetic analysis](#)

[Laboratory techniques and the WHO classification of tumours of haemopoietic and lymphoid tissues](#)

[Conclusions](#)

[Selected bibliography](#)

Chapter 20 Acute myeloid leukaemia

Disease epidemiology

Pathophysiology and clinical features

Disease classification

Cytogenetics and molecular genetics

Treatment

Factors influencing the risk of relapse

Detection of measurable/minimal residual disease (MRD)

Impact of prognostic factors on treatment choice

Acute promyelocytic leukaemia

Treatment in the older patient

Management of relapse

Future developments

Selected bibliography

Chapter 21 Adult acute lymphoblastic leukaemia

Introduction

Diagnosis of adult ALL

Prognostic and predictive factors in ALL

Initial approach to a patient with ALL

Supportive care (see also Chapter 23)

Specific treatment of ALL

Specific approaches to defined clinical populations in the treatment of ALL

Selected bibliography

Chapter 22 Childhood acute lymphoblastic leukaemia

Introduction

Epidemiology

Aetiology

[Pathogenesis \(Figure 22.1\)](#)

[Clinical features](#)

[Differential diagnosis](#)

[Laboratory features](#)

[Immunophenotypic classification \(see also Chapter 19\)](#)

[Cytogenetic and molecular classification](#)

[Prognostic factors](#)

[Treatment](#)

[Future strategies and conclusions](#)

[Acknowledgements](#)

[Selected bibliography](#)

[Chapter 23 Supportive care in the management of leukaemia](#)

[Introduction](#)

[Psychological](#)

[Reproductive](#)

[Anaemia](#)

[Thrombocytopenia](#)

[Infections](#)

[Chemotherapy-induced nausea and vomiting \(CINV\)](#)

[Nutritional](#)

[Metabolic complications](#)

[Skin, nail and dental problems](#)

[Pain](#)

[Palliation](#)

[Selected bibliography](#)

[Chapter 24 Chronic myeloid leukaemia](#)

[Introduction](#)

[Epidemiology and aetiology](#)

[Clinical features, natural history, laboratory haematology and cytogenetics](#)

[Treatment](#)

[Atypical CML/chronic neutrophilic leukaemia \(see also Chapters 25 and 26\)](#)

[Prospects](#)

[Acknowledgement](#)

[Selected bibliography](#)

[Chapter 25 The myelodysplastic syndromes](#)

[Introduction](#)

[History](#)

[Incidence](#)

[Aetiology](#)

[Classification](#)

[Pathogenesis](#)

[Immunological abnormalities in MDS](#)

[Apoptosis in MDS](#)

[Cytogenetic abnormalities in MDS](#)

[Molecular basis of MDS](#)

[Diagnosis](#)

[Natural history and prognostic factors](#)

[International Prognostic Scoring System](#)

[WHO Classification-based Prognostic Scoring System](#)

[Revised International Prognostic Scoring System](#)

[Molecular mutations and prognostic scoring systems](#)

[Management and treatment](#)

[Myelodysplastic/myeloproliferative diseases](#)

[Future directions](#)

[Selected bibliography](#)

[Chapter 26 Myeloproliferative neoplasms](#)

[Introduction](#)

[The polycythaemias](#)

[Essential thrombocythaemia](#)

[Primary myelofibrosis](#)

[Mastocytosis](#)

[Clonal hypereosinophilic syndromes](#)

[Chronic neutrophilic leukaemia](#)

[Neutrophilic chronic myeloid leukaemia](#)

[Transient abnormal myelopoiesis of Down syndrome](#)

[Selected bibliography](#)

[Chapter 27 Chronic lymphocytic leukaemia and other chronic B-cell disorders](#)

[Introduction](#)

[General aspects of diagnostic methodology \(see also Chapter 19\)](#)

[Chronic lymphocytic leukaemia](#)

[Other B-cell chronic disorders](#)

[The leukaemic phase of indolent NHL](#)

[Acknowledgements](#)

[Selected bibliography](#)

[Chapter 28 T-cell lymphoproliferative disorders](#)

[Introduction](#)

[Chronic T-cell leukaemias](#)

[Peripheral T-cell non-Hodgkin lymphomas](#)

[Cutaneous T-cell non-Hodgkin lymphomas](#)

[Conclusions](#)

[Acknowledgements](#)

[Selected bibliography](#)

[Chapter 29 Multiple myeloma](#)

[Definition](#)

[Epidemiology and aetiology](#)

[Pathogenesis](#)

[Differential diagnosis](#)

[Other special forms of plasma cell dyscrasia](#)

[Disease complications and their management](#)

[Prognostic factors](#)

[Treatment](#)

[Acknowledgements](#)

[Selected bibliography](#)

[Chapter 30 Amyloidosis](#)

[Introduction](#)

[Pathogenesis of amyloid](#)

[Systemic AL amyloidosis](#)

[Localized AL amyloidosis](#)

[Other forms of systemic amyloidosis](#)

[Conclusion and future directions](#)

[Selected bibliography](#)

[Chapter 31 The classification of lymphomas: updating the WHO classification](#)

[Introduction](#)

[Mature B-cell neoplasms](#)

[Mature NK-cell/T-cell neoplasms \(see also Chapter 28\)](#)

[Hodgkin lymphoma \(see also Chapter 32\)](#)

[Selected bibliography](#)

[Chapter 32 Hodgkin lymphoma](#)

[Introduction](#)

[Pathological features](#)

[Clinical features](#)

[Staging and risk stratification](#)

[Management](#)

[Conventional frontline treatment](#)

[Risk-adapted frontline treatment](#)

[Relapsed/refractory disease](#)

[Treatment of older patients](#)

[Late effects](#)

[Conclusion](#)

[Selected bibliography](#)

[Chapter 33 Non-Hodgkin lymphoma: low grade](#)

[Introduction](#)

[Epidemiology](#)

[Histology and classification of low-grade NHL](#)

[Follicular lymphoma](#)

[Marginal-zone lymphomas](#)

[Waldenström macroglobulinaemia](#)

[Mantle-cell lymphoma](#)

[Selected bibliography](#)

[Chapter 34 Non-Hodgkin lymphoma: high grade](#)

[Introduction](#)

[Epidemiology](#)

[Classification of high-grade lymphomas](#)

[Aetiology](#)

[Molecular basis of lymphomas \(see also Chapter 18\)](#)

[Diagnosis](#)

[Staging](#)

[Treatment](#)

[Diffuse large B-cell lymphoma](#)

[Primary mediastinal \(thymic\) large B-cell lymphoma](#)

[Intravascular large B-cell lymphoma](#)

[Burkitt lymphoma](#)

[B cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma](#)

[Transformed lymphomas \(see also Chapter 33\)](#)

[Double-hit or triple-hit lymphomas](#)

[DLBCL in HIV-positive patients](#)

[Primary central nervous system lymphoma](#)

[Post-transplant lymphoproliferative disorder](#)

[CNS prophylaxis in high-grade non-Hodgkin lymphoma](#)

[Suggested algorithm for therapy of aggressive non-Hodgkin lymphoma \(summary\)](#)

[Rare aggressive T-cell and NK-cell lymphomas \(see also Chapter 31\)](#)

[Future directions](#)

[Selected bibliography](#)

[Chapter 35 Stem cell transplantation](#)

[Immunological basis of stem cell transplantation](#)

[Stem cell engraftment](#)

[Stem cell mobilization](#)

[Conditioning regimens: basic principles](#)

[Clinical management of patients undergoing stem cell transplantation](#)

[Patient factors determining outcome after allogeneic stem cell transplantation](#)

[Indications for transplantation](#)

[Factors determining the choice of an allogeneic stem cell donor: the donor algorithm](#)

[Management of disease relapse](#)

[Future developments in stem cell transplantation](#)

[Selected bibliography](#)

[Chapter 36 Normal haemostasis](#)

[Introduction](#)

[Overview of haemostasis](#)

[Blood vessels](#)

[Coagulation factors](#)

[Naturally occurring inhibitors of blood coagulation](#)

[Fibrinolysis](#)

[Selected bibliography](#)

[Chapter 37 The vascular function of platelets](#)

[Introduction](#)

[Platelet structure and organelles](#)

[Animal models](#)

[Platelet formation](#)

[Thrombus formation](#)

[Stimulatory receptors and their signalling pathways](#)

[Second messenger pathways underlying activation](#)

[The molecular basis of platelet activation](#)

[Platelet-based bleeding problems](#)

[Platelet function testing](#)

[Platelets and thrombosis](#)

[Genetics of platelet function disorders](#)

[Conclusions and future developments](#)

[Acknowledgements](#)

[Selected bibliography](#)

[Chapter 38 Haemophilia and Von Willebrand Disease](#)

[Introduction](#)

[Haemophilia](#)

[Gene therapy for haemophilia](#)

[Haemophilia A and B in females](#)

[von Willebrand disease](#)

[Selected bibliography](#)

[Chapter 39 Rare inherited coagulation disorders](#)

[Introduction](#)

[Clinical symptoms](#)

[Classification](#)

[Laboratory diagnosis](#)

[Molecular diagnosis](#)

[Global haemostasis tests](#)

[Treatment](#)

[Fibrinogen deficiency](#)

[Prothrombin deficiency](#)

[Factor V deficiency](#)

[Combined deficiency of factor V and factor VIII](#)

[Factor VII deficiency](#)

[Factor X deficiency](#)

[Factor XI deficiency](#)

[Factor XIII deficiency](#)

[Vitamin-K-dependent coagulation factors deficiency](#)

[Concluding remarks](#)

[Acknowledgements](#)

[Selected bibliography](#)

[Chapter 40 Acquired coagulation disorders](#)

[Introduction](#)

[Tests of coagulation and point-of-care testing](#)

[Disseminated intravascular coagulation](#)

[Haemostatic dysfunction in acute promyelocytic leukaemia](#)

[Vitamin K and related disorders](#)

[Haemostatic disturbance in liver disease \(Figure 40.5\)](#)

[Haemostatic disturbance in renal disease](#)

[Pregnancy-related haemostatic dysfunction](#)

[Haemostatic dysfunction associated with cardiopulmonary bypass surgery](#)

[Haemostatic dysfunction associated with trauma](#)

[Coagulopathy in massive blood loss](#)

[Bruising](#)

[Haemostatic dysfunction associated with vasculitis](#)

[Arteriovenous malformations](#)

[Microthromboembolic disease](#)

[Haemostatic dysfunction associated with paraproteinaemia and amyloidosis](#)

[Acquired inhibitors of coagulation factors](#)

[Selected bibliography](#)

[Chapter 41 Congenital platelet disorders](#)

[Introduction](#)

[Thrombocytopenias](#)

[Thrombocytopathies](#)

[Treatment](#)

[Conclusions](#)

[Selected bibliography](#)

[Chapter 42 Primary immune thrombocytopenia](#)

[Introduction](#)

[Clinical features](#)

[Reaching a consensus on terminology](#)

[Pathophysiology](#)

[ITP is multifactorial](#)

[T cells may also be involved](#)

[Natural history of ITP](#)

[Diagnosis](#)

[Management](#)

[Patients with refractory ITP](#)

[TPO receptor agonists](#)

[ITP in children](#)

[ITP in pregnancy \(see also Chapter 50\)](#)

[Selected bibliography](#)

[Chapter 43 Thrombotic thrombocytopenic purpura and haemolytic-uraemic syndrome \(congenital and acquired\)](#)

[Historical introduction](#)

[Thrombotic thrombocytopenic purpura](#)

[Haemolytic uraemic syndrome](#)

[Concluding remarks](#)

[Selected bibliography](#)

[Chapter 44 Heritable thrombophilia](#)

[Introduction](#)

[Heritable thrombophilias associated with venous thrombosis](#)

[Treatment of patients with venous thrombosis and heritable thrombophilias](#)

[Case finding](#)

[Prevention of thrombosis associated with oestrogen-containing hormone preparations](#)

[Prevention of pregnancy-associated venous thrombosis](#)

[Purpura fulminans](#)

[Vitamin K antagonist-induced skin necrosis](#)

[Thrombophilia and arterial thrombosis](#)

[Neonatal stroke \(see also Chapter 50\)](#)

[Laboratory methodology and testing strategy](#)

[Counselling and genetic testing](#)

[Selected bibliography](#)

[Chapter 45 Acquired venous thrombosis](#)

[Epidemiology of venous thromboembolism \(VTE\)](#)

[Pregnancy and venous thromboembolism](#)

[Immobility as a risk factor for venous thromboembolism](#)

[Iatrogenic venous thromboembolism](#)

[Antiphospholipid syndrome](#)

[Venous thromboembolism and cancer](#)

[Thrombotic risk in myeloproliferative disease \(polycythaemia rubra vera and essential thrombocythaemia\) \(see also Chapter 26\)](#)

[Inflammation and thrombosis](#)

[Haematological prothrombotic states due to non-malignant diseases of the blood and bone marrow](#)

[Selected bibliography](#)

[Chapter 46 Antithrombotic agents](#)

[Heparins](#)

[Direct thrombin inhibitors](#)

[Vitamin K antagonists \(VKA\)](#)

[Non-vitamin K antagonist oral anticoagulants \(NOACs\)](#)

[Antiplatelet drugs](#)

[Selected bibliography](#)

[Chapter 47 Management of venous thromboembolism](#)

[Introduction](#)

[Diagnosis of deep vein thrombosis](#)

[Diagnosis of pulmonary embolism](#)

[Treatment of VTE](#)

[Long-term complications of VTE](#)

[Risk of recurrence and duration of anticoagulant therapy](#)

[Other treatments](#)

[Venous thrombosis in unusual sites](#)

[Selected bibliography](#)

[Chapter 48 Haematological aspects of systemic disease](#)

[Anaemia of chronic disease](#)

[Malignancy](#)

[Connective tissue disorders \(Table 48.8\)](#)

[Renal disease \(Table 48.9\)](#)

[Endocrine disease \(Table 48.10\)](#)

[Liver disease \(Table 48.11\)](#)

[Infections \(Tables 48.12 and 48.13\)](#)

[Haematological aspects of pregnancy \(Table 48.15\)](#)

[Anaemia in the elderly](#)

[Haematological aspects of HIV infection \(Table 48.16\)](#)

[Selected bibliography](#)

[Chapter 49 Haematological aspects of tropical diseases](#)

[Introduction](#)

[Ethnic variations in reference ranges](#)

[Tropical diseases with organisms in peripheral blood or bone marrow](#)

[Tropical diseases associated with changes in FBC and / or coagulation](#)

[Non-specific haematological abnormalities associated with tropical diseases](#)

[Selected bibliography](#)

[Chapter 50 Neonatal haematology](#)

[Developmental haemopoiesis](#)

[Neonatal anaemia](#)

[White cell disorders](#)

[Haemostasis and thrombosis in the newborn](#)

[Selected bibliography](#)

[Chapter 51 WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues \(2008\)](#)

[Myeloproliferative neoplasms](#)

[Myelodysplastic/myeloproliferative neoplasms](#)

[Myelodysplastic syndromes](#)

[Acute myeloid leukaemia](#)

[Precursor lymphoid neoplasms](#)

[Mature B-cell neoplasms](#)

[Mature T-cell and NK-cell neoplasms](#)

[Hodgkin lymphoma](#)

[Histiocytic and dendritic cell neoplasms](#)

[Post-transplant lymphoproliferative disorders](#)

[Notes](#)

[Index](#)

[EULA](#)

List of Tables

[Chapter 3](#)

[**Table 3.1**](#)

[**Table 3.2**](#)

[**Table 3.3**](#)

[**Table 3.4**](#)

[**Table 3.5**](#)

[**Table 3.6**](#)

[Chapter 4](#)

[**Table 4.1**](#)

[**Table 4.2**](#)

[**Table 4.3**](#)

[**Table 4.4**](#)

[Chapter 5](#)

[**Table 5.1**](#)

[**Table 5.2**](#)

[**Table 5.3**](#)

[**Table 5.4**](#)

[**Table 5.5**](#)

[**Table 5.6**](#)

[Chapter 6](#)

Table 6.1

Table 6.2

Table 6.3

Chapter 7

Table 7.1

Table 7.2

Table 7.3

Table 7.4

Chapter 8

Table 8.1

Table 8.2

Table 8.3

Table 8.4

Table 8.5

Table 8.6

Table 8.7

Table 8.8

Chapter 9

Table 9.1

Table 9.2

Table 9.3

Table 9.4

Table 9.5

Table 9.6

Table 9.7